Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A second human glucagon-like peptide 1 (glp-1) analog/receptor agonist has been approved by the FDA for the treatment of type 2 diabetes mellitus (DM2).

Liraglutide Injection (Victoza®)